WO2006012046A2 - Preparation of aminophosphines - Google Patents

Preparation of aminophosphines Download PDF

Info

Publication number
WO2006012046A2
WO2006012046A2 PCT/US2005/021376 US2005021376W WO2006012046A2 WO 2006012046 A2 WO2006012046 A2 WO 2006012046A2 US 2005021376 W US2005021376 W US 2005021376W WO 2006012046 A2 WO2006012046 A2 WO 2006012046A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
substituted
added
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/021376
Other languages
English (en)
French (fr)
Other versions
WO2006012046A3 (en
Inventor
Neil Warren Boaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Chemical Co
Original Assignee
Eastman Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chemical Co filed Critical Eastman Chemical Co
Priority to EP05762763A priority Critical patent/EP1758845B1/en
Priority to DE602005011432T priority patent/DE602005011432D1/de
Priority to JP2007518136A priority patent/JP2008504262A/ja
Publication of WO2006012046A2 publication Critical patent/WO2006012046A2/en
Publication of WO2006012046A3 publication Critical patent/WO2006012046A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00Metallocenes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2282Unsaturated compounds used as ligands
    • B01J31/2295Cyclic compounds, e.g. cyclopentadienyls
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2495Ligands comprising a phosphine-P atom and one or more further complexing phosphorus atoms covered by groups B01J31/1845 - B01J31/1885, e.g. phosphine/phosphinate or phospholyl/phosphonate ligands
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/16Preparation of optical isomers
    • C07C231/18Preparation of optical isomers by stereospecific synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/36Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00Metallocenes
    • C07F17/02Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657154Cyclic esteramides of oxyacids of phosphorus
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/32Addition reactions to C=C or C-C triple bonds
    • B01J2231/323Hydrometalation, e.g. bor-, alumin-, silyl-, zirconation or analoguous reactions like carbometalation, hydrocarbation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/44Allylic alkylation, amination, alkoxylation or analogues
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/50Redistribution or isomerisation reactions of C-C, C=C or C-C triple bonds
    • B01J2231/52Isomerisation reactions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60Reduction reactions, e.g. hydrogenation
    • B01J2231/64Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/822Rhodium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/842Iron

Definitions

  • This invention pertains to a novel process for the preparation of certain aminophosphines. More specifically, this invention pertains to a process for the preparation of phosphine-aminophosphines that are useful in the formation of catalysts useful in carrying out a wide variety of reactions such as asymmetric hydrogenations, asymmetric reductions, asymmetric hydroborations, asymmetric olefin isomerizations, asymmetric hydrosilations, asymmetric allylations, asymmetric conjugate additions, and asymmetric organometallic additions.
  • Asymmetric catalysis is the most efficient method for the generation of products with high enantiomeric purity, as the asymmetry of the catalyst is multiplied many times over in the generation of the chiral product. These chiral products have found numerous applications as building bocks for single enantiomer pharmaceuticals as well as in some agrochemicals.
  • the asymmetric catalysts employed can be enzymatic or synthetic in nature. The latter types of catalyst have much greater promise than the former due to much greater latitude of applicable reaction types.
  • Synthetic asymmetric catalysts are usually composed of a metal reaction center surrounded by one or more organic ligands. The ligands usually are generated in high enantiomeric purity, and are the agents inducing the asymmetry.
  • phosphine-aminophosphine ligands which are readily prepared and air-stable, and have been described by Boaz, N. W. and Debenham, S. D., U.S. Patent 6,590,115.
  • the phosphine-aminophosphine compounds disclosed in U.S. 6,590,115 may be combined with catalytically-active metals to form complexes useful as catalysts in asymmetric hydrogenation processes.
  • Compounds that may be obtained from such asymmetric hydrogenation processes are of great interest in the pharmaceutical industry and include, but are not limited to, amino acids, 2-substituted succinates, and 2-hydroxyesters having high enantiomeric purity.
  • US 6590115 discloses the synthesis of phosphino- aminophosphines by a three-step process wherein (1) a dialkylamine-phosphine compound is reacted with a carboxylic acid anhydride to obtain the corresponding phosphine-ester compound; (2) the phosphine-ester compound is reacted with a primary amine to obtain a secondary amine-phosphine compound; and (3) the secondary amine-phosphine compound is reacted with a disubstituted phosphine halide.
  • the third step of the published synthesis of the phosphine-aminophosphine compounds involves the coupling of the precursor secondary amine- phosphine compound with a suitably substituted dialkyl, diaryl, or alkyl aryl phosphine halide.
  • This method is limited by several factors. For example, there are only a limited number of chlorophosphines that are commercially available and the preparation of disubstituted phosphine halide is often arduous.
  • coupling of the amine with the phosphine halide may be subject to severe steric constraints, which may limit the types of substituents that may be present on the nitrogen atom of the secondary amine-phosphine reactant and/or on the phosphorus atom of the disubstituted phosphine halide reactant.
  • R, R 1 , R 2 , and R 3 are the same or different and are selected from branched- or straight-chain C1-C20 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 2 O carbocyclic aryl, or C 4 -C 2O heteroaryl wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen;
  • L is a divalent chiral radical selected from branched- or straight- chain C 1 -C- 2 0 alkylene, C 3 -C 8 cycloalkylene, C 6 -C 2 O carbocyclic arylene, C 4 - C 20 heteroarylene wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen, or metallocenylmethylene, wherein L is substantially enantiomerically pure, i.e., an enantiomeric excess of 90% or greater;
  • X is halide
  • M 1 is a metal selected from Group I and Group Il metals including magnesium halide residues MgX of Grignard reactants R 1 -MgX and R 2 - MgX.
  • R 1 -MgX and R 2 - MgX are metals selected from Group I and Group Il metals including magnesium halide residues MgX of Grignard reactants R 1 -MgX and R 2 - MgX.
  • R 1 R 1 , R 2 , R 3 and L may be either substituted or unsubstituted.
  • our novel process is carried out in an inert organic solvent.
  • examples include cyclic or acyclic ethers such as diethyl ether, diisopropyl ether, tert-butyl methyl ether and tetrahydrofuran (THF); aromatic hydrocarbons such as benzene, toluene, and xylene (including mixed xylene isomers); aliphatic and alicyclic hydrocarbons such as hexane, heptane, and cyclohexane; and mixtures of any two or more of the foregoing.
  • the preferred solvent is toluene, xylenes, tert-butyl methyl ether, or tetrahydrofuran.
  • Step (1) is carried out in the presence of an acid acceptor, e.g., a compound that will react with and thus scavenge or consume the hydrogen halide generated by the reaction of step (1).
  • the acid acceptor preferably is a C 3 -C 15 tertiary amine or pyridine, with the preferred amines being triethylamine and diisopropylethylamine.
  • the amount of acid acceptor present is typically 1 to 5 moles, preferably 1 to 2 moles, per mole of reactant 2.
  • the reactant 2 employed in step (1) may be obtained or made by a variety of methods, such as in US 6,590,115.
  • the relative amounts of reactant 2 and phosphorus trihalide PX 3 employed in step (1 ) typically provides a reactant 2 to phosphorus trihalide PX 3 mole ratio of 0.5:1 to 4:1 , preferably 1 :1 to 1.5:1.
  • results of subsequent reactions indicate that the intended dihaloaminophosphine 5 produced in this reaction (i.e., when L is a metallocenylmethylene) is substantially uncontaminated with monohalodiaminophosphine and triaminophosphine. This is surprising, as a statistical mixture of these species might be expected.
  • Phosphorus trihalide PX 3 may be any trihalide such as tifluoride, trichloride, tribromide or triiodide but preferably is phosphorus trichloride.
  • Step (1) of the process may be carried out at a temperature between -100 0 C and the boiling point of the inert, organic solvent, preferably at a temperature of -8O 0 C to 6O 0 C. Although it is not necessary to do so, dihalide intermediate 3 may be isolated before conducting the second step of the process.
  • step (2) of the process intermediate 3 is contacted with one or more reactants having the formula R 1 -M 1 , R 2 -M 1 or a mixture thereof in the presence of an inert, organic solvent (e.g., one or more of the solvents described above).
  • the amounts of R 1 -M 1 and/or R 2 -M 1 employed normally provides a mole ratio of R 1 -M 1 /R 2 -M 1 to phosphorus trihalide PX 3 used in step (.1) of 3:1 to 6:1, preferably 3:1 to 4:1.
  • Step (2) may be carried out at a temperature between -100 0 C and the boiling point of the solvent, preferably -8O 0 C to 25 0 C.
  • M 1 preferably is MgBr, MgCI, MgI, Li, Na, or K.
  • the product of the process having formula 1 may be isolated from the reaction mixture using methods known to those skilled in the art, e.g., by extraction, filtration, or crystallization.
  • the product of formula 1 may be purified if necessary using conventional procedures such as extraction, chromatography, or crystallization.
  • the phosphinoamino-phosphine compounds prepared in accordance with the process of our invention preferably employ an L group that is a metallocenylmethylene, which provides a compound having formula 4 or 5 (the enantiomer of 4):
  • R, R 1 , R 2 and R 3 are as defined above;
  • R 4 , R 5 , and R 6 are, independently, hydrogen, branched- or straight- chain C 1 -C 2 0 alkyl, C-3-C ⁇ cycloalkyl, Ce-C 2 O carbocyclic aryl, or C4-C 20 heteroaryl wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen;
  • n is 0 to 3;
  • m is O to 5;
  • M 2 is a metal from the metals of Groups IVB, VB, VIB, VIIB or VIII.
  • a particularly preferred group of phosphinoamino-phosphine compounds that may be synthesized in accordance with our invention have formulas 4 and 5 wherein R is aryl, most preferably phenyl; R 1 and R 2 are the same substituents selected from aryl, C 2 -C 6 alkyl, or C 3 -C 6 cycloalkyl, most preferably phenyl, p-methoxyphenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3-fluorophenyl, or 4-fluorophenyl; R 3 is hydrogen, Ci to C 6 alkyl, or aryl; R 4 is hydrogen, Ci to C 6 alkyl, benzyl, racemic or substantially enantiomerically pure 1-phenyleth
  • R 3 , R 4 , R 5 , R 6 , and L may be straight- or branched-chain aliphatic hydrocarbon radicals containing up to 20 carbon atoms and may be substituted, for example, with one to three groups selected from Ci-C 6 - alkoxy, cyano, C 2 -C 6 -alkoxycarbonyl, C 2 -C 6 -aIkanoyloxy, aryl and halogen.
  • Ci-C 6 -alkoxy C 2 -C 6 -alkoxycarbonyr, and 1I C 2 -C 6 -alkanoyloxy
  • R 7 is CrCe-alkyl or substituted Ci-C 6 - alkyl.
  • C 3 - Cs-cycloalkyl is used to denote a saturated, carbocyclic hydrocarbon radical having three to eight carbon atoms.
  • the aryl groups which each of R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and L may represent may include phenyl, naphthyl, or anthracenyl and phenyl, naphthyl, or anthracenyl substituted with one to three substituents selected from Ci-C 6 - alkyl, substituted CrCeralkyl, C 6 -Ci 0 aryl, substituted C 6 -Ci 0 aryl, CrC 6 -alkoxy, halogen, cyano, CrC 6 -alkanoyloxy, Ci-C 6 -alkylthio, Ci-C ⁇ -alkylsulfonyl, trifluoromethyl, C 2 -C 6 -alkoxycarbonyl, C 2 -
  • C 6 -alkanoylamino and -O-R 8 S-R 8 , -SO 2 -R 8 , -NHSO 2 R 8 and -NHCO 2 R 8 , wherein R 8 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from CrC 6 -alkyl, C 6 -C 10 aryl, Ci-C 6 -alkoxy and halogen.
  • the C 4 -C 20 heteroaryl radicals described herein include a 5- or 6- membered aromatic ring containing one to three heteroatoms selected from oxygen, sulfur and nitrogen.
  • heteroaryl groups examples include thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidyl, benzoxazolyi, benzothiazolyl, benzimidazolyl, indolyl and the like.
  • the heteroaryl radicals may be substituted, for example, with up to three groups such as C-j-C ⁇ -alkyl, Ci-C 6 -alkoxy, substituted CrC 6 -alkyl, halogen, C 1 -C 6 - alkylthio, aryl, arylthio, aryloxy, C 2 -C 6 -alkoxycarbonyl and C 2 -C 6 - alkanoylamino.
  • the heteroaryl radicals also may be substituted with a fused ring system, e.g., a benzo or naphtho residue, which may be unsubstituted or substituted, for example, with up to three of the groups set forth in the preceding sentence.
  • halogen is used to include fluorine, chlorine, bromine, and iodine.
  • each of the references herein to groups or moieties having a stated range of carbon atoms includes not only the Ci group (methyl) and C 6 group (hexyl) end points, but also each of the corresponding individual C 2 , C 3 , C 4 and C 5 groups.
  • each of the individual points within a stated range of carbon atoms may be further combined to describe subranges that are inherently within the stated overall range.
  • the term "Ci-C 6 -alkyl” includes not only the individual moieties Ci through Ce, but also contemplates subranges such as "C 2 -C 5 -alkyl.”
  • Complexes of the phosphine-aminophosphine compounds of formula 1 with a catalytically-active metal are effective catalysts for promoting a large number of possible reactions employing a wide variety of reactants. Examples of possible reactions include asymmetric hydrogenations, asymmetric reductions, asymmetric hydroborations, asymmetric olefin isomerizations, asymmetric hydrosilations, asymmetric allylations, asymmetric conjugate additions and asymmetric organometallic additions.
  • the particular metal selected for complexation with the phosphine-aminophosphine compounds of formula 1 depends on the desired reaction.
  • the metal may be selected from Group VIII metals with iridium, ruthenium and, especially, rhodium being preferred.
  • the complexes may be prepared and isolated prior to use, it is preferable to prepare the complex in situ from phosphine-aminophosphine compound 1 and a metal pre-catalyst.
  • the relative amounts of phosphine- aminophosphine compound 1 and catalytically-active metal employed typically provide a phosphorus:metal atomic ratio of 1 :1 to 4:1 , preferably 2:1 to 3:1.
  • the complexes of the phosphine-aminophosphine compounds of formula 1 with a catalytically-active metal are especially useful in performing asymmetric hydrogenation reactions which constitutes another embodiment of our invention.
  • the present invention includes a process for the hydrogenation of a hydrogenatable compound which comprises contacting the hydrogenatable compound with hydrogen in the presence of a catalyst complex of a phosphine-aminophosphine compound of formula 1 with a catalytically-active metal under hydrogenation conditions of temperature and pressure.
  • the catalytically- active metal complexed preferably is rhodium, iridium, or ruthenium, and most preferably is rhodium.
  • the amount of complex utilized in the hydrogenation process may vary between 0.00005 and 0.5 molar equivalents based on the reactant compound, with more complex usually providing faster reaction rates.
  • the reaction atmosphere is hydrogen, but may also contain other materials that are inert to the reaction conditions.
  • the reaction can be run at atmospheric pressure or at elevated pressure, e.g., from 0.5 to 200 gauge (barg).
  • the reaction is run at a temperature which affords a reasonable rate of conversion, which can be as low as - 5O 0 C but is usually between ambient temperature and the boiling point (or apparent boiling point at elevated pressure) of the lowest boiling component of the reaction mixture.
  • Toluene (10 ml_) was added to a 100-mL 3-necked flask which was cooled in ice to below 5 0 C.
  • Phosphorus trichloride (0.26 mL; 3.0 mmol; 1.0 equiv based on 2a) was added followed by triethylamine (0.50 mL; 3.6 mmol; 1.2 equiv).
  • (R)- ⁇ /-methyl-1-[(S)-2-(diphenylphosphino)- ferrocenyl]ethylamine (2a)(1.26 g; 3.0 mmol) dissolved in 10 mL of toluene was added over about 5 minutes such that the temperature remained below 10 0 C.
  • the reaction mixture was allowed to warm to ambient temperature over 30 min and stirred at ambient temperature for 2 hours.
  • the reaction mixture was cooled in ice to below 5 0 C and a 3.0 M solution of phenylmagnesium bromide in diethyl ether (3.5 mL; 10.5 mmol; 3.5 equiv) was added over approximately 10 minutes such that the temperature remained below 1O 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to thin layer chromatography (tic) analysis.
  • the mixture was cooled in ice-water and saturated aqueous sodium bicarbonate solution (20 mL) was added at a rate such that the temperature remained below 15°C.
  • the reaction mixture was cooled to below -70 0 C and a 3.0 M solution of phenylmagnesium bromide in diethyl ether (2.33 mL; 7.0 mmol; 3.5 equiv) was added such that the temperature remained below -50 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2b according to tic analysis.
  • Heptane 25 mL was added and the reaction mixture was quenched by the addition of acetone (0.78 mL; 5 equiv).
  • the mixture was filtered, the precipitate was washed with ethyl acetate, and the filtrate was stripped.
  • Toluene (10 ml_) was added to a 100-mL 3-necked flask which was cooled to below -70 0 C in a dry ice-acetone bath.
  • Phosphorus trichloride (174 ⁇ l_; 2.0 mmol; 1.0 equiv based on 2c) was added followed by triethylamine (0.33 mL; 2.4 mmol; 1.2 equiv).
  • the reaction mixture was cooled to below -70 0 C and a 3.0 M solution of phenylmagnesium bromide in diethyl ether (2.33 mL; 7.0 mmol; 3.5 equiv) was added such that the temperature remained below -50 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2c according to tic analysis.
  • Heptane 25 mL was added and the reaction mixture was quenched by the addition of acetone (0.78 mL; 5 equiv).
  • the mixture was filtered through celite, the precipitate was washed with ethyl acetate, and the filtrate was stripped.
  • reaction mixture was allowed to warm to ambient temperature overnight.
  • the mixture was cooled in ice-water and heptane (20 mL) was added.
  • Saturated aqueous sodium bicarbonate solution (10 mL) was added at a rate such that the temperature remained below 10 0 C.
  • the layers were separated, the aqueous solution was filtered to remove insolubles, and it was extracted twice with ethyl acetate.
  • the combined organic extracts were dried with magnesium sulfate and concentrated to afford 1.56 g of crude product.
  • Toluene (5 mL) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (234 ⁇ L; 2.68 mmol; 1.0 equiv based on 2f) was added followed by triethylamine (0.45 mL; 3.22 mmol; 1.2 equiv).
  • the reaction mixture was stirred at ⁇ 5°C for 45 min, warmed to ambient temperature for 2 h, then was cooled to ⁇ 5°C and a 3.0 M solution of phenylmagnesium bromide in diethyl ether (3.15 ml_; 9.4 mmol; 3.5 equiv) was added such that the temperature remained below 15°C.
  • the reaction mixture was allowed to warm to ambient temperature overnight.
  • the mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (10 mL) was added at a rate such that the temperature remained below 10 0 C.
  • Toluene (5 mL) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (131 ⁇ L; 1.50 mmol; 1.0 equiv based on 2g) was added followed by triethylamine (0.25 mL; 1.80 mmol; 1.2 equiv).
  • the reaction mixture was allowed to warm to ambient temperature for one hour and stirred at ambient temperature for 6 hours, then was cooled to ⁇ 5°C and a 3.0 M solution of phenylmagnesium bromide in diethyl ether (1.75 mL; 5.25 mmol; 3.5 equiv) was added such that the temperature remained below 10 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight.
  • the mixture was cooled in ice-water and heptane (15 ml_) was added.
  • Saturated aqueous sodium bicarbonate solution (10 ml_) was added at a rate such that the temperature remained below 1O 0 C.
  • Toluene (10 ml_) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (218 ⁇ L; 2.50 mmol; 1.0 equiv based on 2h) was added followed by triethylamine (0.42 mL; 3.0 mmol; 1.2 equiv).
  • the reaction mixture was allowed to warm to ambient temperature for one hour and stirred at ambient temperature for 27 hours, then was cooled to ⁇ 5°C and a 3.0 M solution of phenylmagnesium bromide in diethyl ether (2.90 mL; 8.73 mmol; 3.5 equiv) was added such that the temperature remained below 1O 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight. The mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (10 mL) was added at a rate such that the temperature remained below 1O 0 C.
  • Toluene (10 ml_) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (174 ⁇ L; 2.0 mmol; 1.0 equiv based on 2a) was added followed by triethylamine (0.33 rnL; 2.4 mmol; 1.2 equiv).
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 mL) was added.
  • Saturated aqueous sodium bicarbonate solution (15 ml_) was added at a rate such that the temperature remained below 10 0 C.
  • the layers were separated, the aqueous solution was filtered to remove insolubles, and it was extracted twice with ethyl acetate.
  • the combined organic extracts were dried with sodium sulfate and concentrated to afford 1.56 g of crude product.
  • reaction mixture was stirred below 5 0 C for 30 minutes and warmed to ambient temperature for 1 hour, then was cooled to ⁇ 5°C and a 0.5 M solution of 3,4-difluorophenylmagnesium bromide in THF (14 mL; 7.0 mmol; 3.5 equiv) was added over about 10 min such that the temperature remained below 10 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (15 mL) was added at a rate such that the temperature remained below 10 0 C.
  • Toluene (10 ml_) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (174 ⁇ l_; 2.0 mmol; 1.0 equiv based on 2a) was added followed by triethylamine (0.33 ml_; 2.4 mmol; 1.2 equiv).
  • reaction mixture was stirred below 5 0 C for 30 minutes and warmed to ambient temperature for 1 hour, then was cooled to ⁇ 5°C and a 0.5 M solution of 3,4-dichlorophenylmagnesium bromide in THF (14 mL; 7.0 mmol; 3.5 equiv) was added over about 10 min such that the temperature remained below 10 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 ml_) was added. Saturated aqueous sodium bicarbonate solution (15 ml_) was added at a rate such that the temperature remained below 10 0 C.
  • Toluene (10 ml_) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (174 ⁇ l_; 2.0 mmol; 1.0 equiv based on 2a) was added followed by triethylamine (0.33 ml_; 2.4 mmol; 1.2 equiv).
  • reaction mixture was stirred below 5 0 C for 30 minutes and warmed to ambient temperature for 3 hours, then was cooled to ⁇ 5°C and a 0.5 M solution of 3,5-difluorophenylmagnesium bromide in THF (14 ml_; 7.0 mmol; 3.5 equiv) was added over about 10 min such that the temperature remained below 10 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (15 mL) was added at a rate such that the temperature remained below 10 0 C.
  • reaction mixture was stirred below 5 0 C for 30 minutes and warmed to ambient temperature for 3 hours, then was cooled to ⁇ 5°C and a 0.5 M solution of 3,5-dichlorophenylmagnesium bromide in THF (14 mL; 7.0 mmol; 3.5 equiv) was added over about 15 min such that the temperature remained below 1O 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (15 mL) was added at a rate such that the temperature remained below 10 0 C.
  • the reaction mixture was stirred below 5 0 C for 30 minutes and warmed to ambient temperature for 2 hours, then was cooled to ⁇ 5°C and a 2.0 M solution of 4-fluorophenylmagnesium bromide in diethyl ether (5.25 mL; 10.5 mmol; 3.5 equiv) was added slowly dropwise such that the temperature remained below 10 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (15 mL) was added at a rate such that the temperature remained below 1O 0 C.
  • Toluene (10 mL) was added to a 100-mL 3-necked flask which was cooled to ⁇ 5°C in an ice bath.
  • Phosphorus trichloride (0.26 mL; 3.0 mmol; 1.0 equiv based on 2a) was added followed by triethylamine (0.50 mL; 3.6 mmol; 1.2 equiv).
  • reaction mixture was stirred below 5 0 C for 30 minutes and warmed to ambient temperature for 2 hours, then was cooled to ⁇ 5°C and a 1.0 M solution of 3-fluorophenylmagnesium bromide in THF (10..5 mL; 10.5 mmol; 3.5 equiv) was added slowly dropwise such that the temperature remained below 1O 0 C.
  • the reaction mixture was allowed to warm to ambient temperature overnight to completely consume 2a according to tic analysis.
  • the mixture was cooled in ice-water and heptane (20 mL) was added. Saturated aqueous sodium bicarbonate solution (15 mL) was added at a rate such that the temperature remained below 10 0 C.
  • Methyl 2-acetamidocinnamate (110 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous tetrahydrofuran (THF, 3.0 mL) and degassed with argon for 15 minutes.
  • Bis(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4a from Example 1 (3.7 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon- degassed anhydrous THF (2.0 mL) was added.
  • Ligand 4a 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (3.0 mL) and degassed with argon for 15 minutes. Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4a from Example 1 (3.7 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (2.0 mL) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of 2-acetamidocinnamic acid.
  • Methyl Lactate using the Rhodium Complex of Ligand 4a Methyl pyruvate (51 mg; 0.50 mmol) was dissolved in a reaction vessel in anhydrous THF (3.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4a from Example 1 (3.7 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous THF (2.0 mL) was added.
  • Methyl 2-acetamidocinnamate (110 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous tetrahydrofuran (THF, 5.0 mL) and degassed with argon for 15 minutes.
  • THF tetrahydrofuran
  • Bis(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4b from Example 2 (3.8 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon- degassed anhydrous THF (0.5 mL) was added.
  • Ligand 4b ltaconic acid (65 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 ml_) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyc!ooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv)
  • ligand 4b from Example 2 (3.8 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 ml_) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of itaconic acid.
  • reaction mixture was stirred for 6 hours, at which point a sample (0.024 mmol) was converted to the methyl ester by the action of trimethylsilyldiazomethane (2.0 M in hexane; 60 ⁇ L; 0.12 mmol; 5 equiv) by stirring in methanol (1 ml_) for 30 min. After acetic acid quench, the sample was analyzed by chiral GC to indicate 14.4% conversion to N-acetyl L- alanine with 93.6% ee.
  • Chiral GC conditions Cyclosil-B [J&W Scientific] 30 m x 0.25 mm ID, 0.25 ⁇ m film thickness, 40-100 0 C 70°C/min, 100 0 C 15 min, 100-170 0 C 15°C/min, 17O 0 C 7 min, 6 psig He 6 min, 6-20 psig He 80 psig/min, 20 psig 22 min.
  • t R [(R)-/V-acetylalanine methyl ester) 19.36 min, t.R[(S)- ⁇ /-acetylalanine methyl ester) 19.12 min, t R (methyl 2-acetamidoacrylate) 17.91 min.
  • Ligand 4e 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4e from Example 5 (4.0 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 mL) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of 2-acetamidocinnamic acid.
  • 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4f from Example 6 (4.1 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 mL) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of 2-acetamidocinnamic acid.
  • Methyl 2-acetamidoacrylate 72 mg; 0.5 mmol was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate 2.3 mg; 5 ⁇ mol; 0.01 equiv
  • ligand 4g from Example 7 4.2 mg; 6 ⁇ mol; 0.012 equiv
  • This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of methyl
  • 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4h from Example 8 (4.2 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 mL) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of 2- acetamidocinnamic acid.
  • Methyl 2-acetamidocinnamate (110 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4i from Example 9 (4.0 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.5 ml_) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of methyl 2-acetamidocinnamate.
  • Benzyl 2-ferf-butoxycarbonylamino-3-cyclopropylacrylate (159 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 ml_) and degassed with argon for 15 minutes.
  • Bis(1 ,5- cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4i from Example 9 (4.0 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.5 ml_) was added.
  • 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4i from Example 9 (4.0 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 mL) was added. This solution was stirred at 25 0 C under argon for 15 minutes and then added to the solution of 2-acetamidocinnamic acid.
  • ltaconic acid (65 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4i from Example 9 (4.0 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 ml_) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of itaconic acid.
  • Benzyl 2-te/f-butoxycarbonylamino-3-cyclopropylacrylate (159 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5- cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4j from Example 10 (4.1 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.5 mL) was added.
  • 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 ml_) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4k from Example 11 (4.5 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 ml_) was added. This solution was stirred at 25 0 C under argon for 15 minutes and then added to the solution of 2- acetamidocinnamic acid.
  • Benzyl 2-te/t-butoxycarbonylamino-3-cyclopropylacrylate (159 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5- cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and iigand 4k from Example 11 (4.5 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.5 ml_) was added.
  • Ligand 4n 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4n from Example 13 (4.5 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon- degassed anhydrous methanol (0.50 mL) was added. This solution was stirred at 25°C under argon for 15 minutes and then added to the solution of 2-acetamidocinnamic acid.
  • 2-Acetamidocinnamic acid (102 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4o from Example 14 (3.9 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.50 mL) was added. This solution was stirred at 25 0 C under argon for 15 minutes and then added to the solution of 2- ace ' tamidocinnamic acid.
  • Benzyl 2-fe/f-butoxycarbonylamino ⁇ 3-cyclopropylacrylate (159 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 mL) and degassed with argon for 15 minutes.
  • Bis(1 ,5- cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4o from Example 14 (3.9 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.5 mL) was added.
  • Methyl 2-acetamidocinnamate (110 mg; 0.5 mmol) was dissolved in a reaction vessel in anhydrous methanol (5.0 ml_) and degassed with argon for 15 minutes.
  • Bis(1 ,5-cyclooctadiene)rhodium trifluoromethanesulfonate (2.3 mg; 5 ⁇ mol; 0.01 equiv) and ligand 4p from Example 15 (3.9 mg; 6 ⁇ mol; 0.012 equiv) were combined and argon-degassed anhydrous methanol (0.5 mL) was added. This solution was stirred at 25 D C under argon for 15 minutes and then added to the solution of methyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
PCT/US2005/021376 2004-06-25 2005-06-16 Preparation of aminophosphines Ceased WO2006012046A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05762763A EP1758845B1 (en) 2004-06-25 2005-06-16 Preparation of aminophosphines
DE602005011432T DE602005011432D1 (de) 2004-06-25 2005-06-16 Herstellung von aminophosphinen
JP2007518136A JP2008504262A (ja) 2004-06-25 2005-06-16 アミノホスフィンの製造

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/876,492 2004-06-25
US10/876,492 US6906213B1 (en) 2004-06-25 2004-06-25 Preparation of aminophosphines

Publications (2)

Publication Number Publication Date
WO2006012046A2 true WO2006012046A2 (en) 2006-02-02
WO2006012046A3 WO2006012046A3 (en) 2006-04-27

Family

ID=34634716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021376 Ceased WO2006012046A2 (en) 2004-06-25 2005-06-16 Preparation of aminophosphines

Country Status (6)

Country Link
US (1) US6906213B1 (cg-RX-API-DMAC7.html)
EP (1) EP1758845B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008504262A (cg-RX-API-DMAC7.html)
AT (1) ATE416154T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005011432D1 (cg-RX-API-DMAC7.html)
WO (1) WO2006012046A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906213B1 (en) * 2004-06-25 2005-06-14 Eastman Chemical Company Preparation of aminophosphines
US6906212B1 (en) * 2004-06-25 2005-06-14 Eastman Chemical Company Phosphine-phosphoramidite compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6590115B2 (en) * 2000-09-29 2003-07-08 Eastman Chemical Company Phosphino-aminophosphines
US6620954B1 (en) * 2002-03-25 2003-09-16 Eastman Chemical Company Phosphinometallocenylamides as novel ligands for asymmetric catalysis
GB0400720D0 (en) * 2004-01-14 2004-02-18 Stylacats Ltd Novel ferrocene-based phosphorus chiral phosphines
US6939981B1 (en) * 2004-06-25 2005-09-06 Eastman Chemical Company Ruthenium complexes of phosphine-aminophosphine ligands
US6906213B1 (en) * 2004-06-25 2005-06-14 Eastman Chemical Company Preparation of aminophosphines
US6906212B1 (en) * 2004-06-25 2005-06-14 Eastman Chemical Company Phosphine-phosphoramidite compounds

Also Published As

Publication number Publication date
WO2006012046A3 (en) 2006-04-27
ATE416154T1 (de) 2008-12-15
EP1758845B1 (en) 2008-12-03
DE602005011432D1 (de) 2009-01-15
US6906213B1 (en) 2005-06-14
JP2008504262A (ja) 2008-02-14
EP1758845A2 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
JP3723241B2 (ja) 光学活性リン化合物
JP5729634B2 (ja) 触媒的不斉付加反応に使用する二座キラル配位子
US6399787B1 (en) Catalytic asymmetric hydrogenation, hydroformylation, and hydrovinylation via transition metal catalysts with phosphines and phosphites
Roucoux et al. New alkylarylamidophosphinephosphinites as chiral diphosphines for asymmetric hydrogenation of activated keto compounds
JPH09249677A (ja) キラルなルテニウム錯体、その製造方法、及びプロキラルなケトンの鏡像選択的なトランスファー水素添加の方法
EP1758844B1 (en) Phosphine-phosphoramidite compounds
JP6006723B2 (ja) ビアリールジホスフィン配位子、それらの中間体、および不斉触媒反応におけるそれらの使用法
Dai et al. Development of a new class of C1-symmetric bisphosphine ligands for rhodium-catalyzed asymmetric hydrogenation
US6906213B1 (en) Preparation of aminophosphines
EP0997470A1 (en) Optically active bisphosphinomethanes and their rhodium and copper complexes for catalytic asymmetric syntheses
US20060135804A1 (en) Tetradentate ligands and metal complexes thereof for asymmetric catalysis
US7081544B2 (en) Chiral ligands, transition metal complexes thereof, and the catalytic use of the same
JP2004517901A (ja) 配位子およびその使用
CA2594893C (en) Metallocene-based chiral phosphines and arsines
JP2011503220A (ja) 不斉付加反応に使用する二座第二級ホスフィンオキシドキラル配位子
CA2549929C (en) Asymmetric imine hydrogenation processes
WO2003016264A1 (en) Process for the preparation of enantiomerically enriched n-acyl-beta-amino acid derivatives by enantioselective hydrogenation of the corresponding (z)-enamides
JP2003176293A (ja) キラル一リン化合物、該化合物を含有する触媒およびキラル化合物の製造方法
US8759541B2 (en) Chiral acyclic diaminocarbene ligands, precursors therefore and their use in organic synthesis reactions
WO1994020510A1 (en) Homogeneous bimetallic hydroformylation catalysts and processes utilizing these catalysts for conducting hydroformylation reactions
US20040186314A1 (en) Process for the preparation of enantiomerically enriched n-acyl-beta-amino acid derivatives by enantioselective hydrogenation of the corresponding (z)-enamides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005762763

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007518136

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005762763

Country of ref document: EP